CHEWY, INC. (CHWY): what the price assumes

In the published model solve dated 2026-Q2, anchored at $23.66, CHEWY, INC. (CHWY) is priced for +43.4% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-07-25.

Generated: 2026-09-07 · Exported: 2026-09-09 · Source: https://boothcheck.com/report/CHWY

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The operating-margin figure is value-band context at year 8: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 11.8% cost of capital with 4% terminal growth over a 5-year stage.

How unusual the bet is: n/a

Valuation X-Ray

Asset, earnings-power and peer-multiple models all land far below the price; ONLY the growth-DCF reaches it. The bet is durable compounding the static frames structurally cannot price (a moat/durability premium).

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that justify the price: Growth Families that call it expensive: Asset, Earnings

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 8.4%); the inversion above states its own rate.

Per-Model Detail (n=16)

Solvency

Bullet Takeaways

• Seven dollars in every ten of revenue is consumables, mostly food and litter bought on a repeating schedule, which is why the company treats its subscription mix as "a key indicator of our recurring sales".
• Operating profit is only 2.7% of revenue, so the promotional response the 10-K warns it may have to make would land on a very thin line indeed.
• At $20.87 the price requires roughly 34.5% annual operating-profit growth sustained for five years, a pace only about 23% of comparable fast growers have held that long.

Bull Case

A bag of dog food is the most forecastable purchase in American retail. The animal eats the same amount every week, the owner does not comparison-shop the tenth reorder, and the delivery either arrives or the household notices immediately. Chewy has built the business around that fact. Consumables are 70% of revenue, and the company measures its subscription programme as "a key indicator of our recurring sales" rather than as a marketing promotion. On top of the food sits the part with better economics: the 10-K opens with the claim that "Chewy operates the #1 pet pharmacy in America." Pet health and specialty products are 16% of revenue, and prescriptions are refills by definition.

The return profile is the part most retail comparisons miss. Trailing return on equity runs near 60.2% against book value of roughly $1.01 a share, which is not a story about extraordinary profitability. It is a story about how little permanent capital the model needs. Customers pay on order; suppliers are paid later; the working capital cycle funds the business rather than consuming it. Equity is a thin sliver of the balance sheet, and profit measured against a thin sliver looks enormous. The practical version is simpler: growth here does not have to be financed.

Among comparable online sellers, the operating line is where the separation shows. Chewy converts about 2.7% of revenue into operating profit. W, at a similar revenue scale, converts about 1.0%, and CPNG converts about 0.2% on a far larger base. Those are small numbers in absolute terms and the bear will say so. What they show is direction of travel: in a category where scale has mostly been used to buy share, this is one of the few large online retailers whose scale is showing up as profit rather than as a slower rate of loss.

The next leg is a mix change rather than a volume change. The company runs veterinary clinics alongside the fulfillment network, launched a practice-management product for veterinarians in 2021 that lets clinics sell through Chewy while it handles logistics, and in its own words "In 2025, we launched Get Real, a Chewy-exclusive private brand of healthy, fresh, and minimally-processed dog food." Private brands and clinic services both carry different economics from reselling a national brand at a discount. Whether the mix shift moves the consolidated margin materially is the open question, and it is the only question that matters at this price.

The capital structure gives it room to try. The 10-K describes a "senior secured asset-based credit facility (the \"ABL Credit Facility\") which matures on April 1, 2030", sized at up to 800 million dollars against a borrowing base of inventory and receivables, alongside a portfolio of investment-grade short and intermediate securities. Real estate is leased rather than owned, with "The terms of the Company's real estate leases generally range from 5 to 15 years". The company is not consuming cash. It has time to find out whether the mix shift works, which is a luxury most retailers at 2.7% operating margins do not have.

Bear Case

The advantage being worn away is the ability to hold price. Chewy's own risk section says it plainly: "In order to effectively compete in the future, we may be required to offer promotions and other incentives, which may result in lower operating margins and in turn adversely affect our results of operations." That sentence is standard in a 10-K and easy to skim past. It is not standard when the operating margin is 2.7%. A discount that a general merchant funds out of a mid-single-digit margin comes out of almost the entire margin here. The filing goes further about who is applying the pressure, warning that competitors' scale "may allow our competitors to derive greater net sales and profits from their existing customer base, acquire customers at lower costs or respond more quickly than we can to new or emerging technologies such as AI and changes in consumer preferences or habits", and listing internet-based competition first among industry risks: "Competition in the pet products and services health and retail industries, especially Internet-based competition, is strong and presents an ongoing threat to the success of our business."

The erosion shows up in what a subscription actually locks in. Autoship secures the reorder, not the price. A household that switched to Chewy for convenience can switch away for the same reason, and the switching cost is one afternoon. Consumables are 70% of revenue, and consumables are the most substitutable thing in the category, which is precisely why the vendor rebate structure matters: the filing notes that "certain vendors provide funding for discounts relating to the Autoship subscription program which are passed on to the Company's customers". Part of the subscription discount is somebody else's money. That is a good arrangement while it lasts and not a durable one if the same vendors extend it to whoever else is selling their food.

Set that against the requirement the price carries. At $20.87 the market pays roughly 25.7 dollars for each dollar of annual operating profit, and that multiple needs operating profit to compound near 34.5% a year for five straight years. Only about 23% of comparable fast growers have sustained a pace like that over that span. The reason the demand is so steep is arithmetic rather than pessimism: 2.7% of revenue is a small base, so tripling operating profit off it is a matter of a few hundred basis points of margin that have to be found in a category where the filing itself flags promotional pressure as the likely direction.

Capital returns deserve a harder look than they usually get here. Stock-based compensation runs near 290 million dollars a year against free cash flow of about 584.5 million dollars, and the share count has fallen only about 0.4% a year over the past four years. Read those together and the repurchase programme is mostly absorbing dilution rather than returning capital. The shareholder receives the appearance of a buyback and roughly the same ownership stake. Control is also concentrated: the filing states that "The Company is controlled by a consortium including private investment funds advised by BC Partners", which means the ordinary shareholder is a passenger on capital-allocation decisions rather than a voter on them.

The last piece is what sits underneath if the growth does not arrive. Of the four families of valuation method used here, only the forward-growth models reach today's price. The price sits about 217% above the asset-value methods, about 137% above the earnings-power methods, and about 33% above the peer-multiple methods. That is not a company with a valuation floor and an upside argument stacked on it. It is a company whose price rests on one lens alone, and that lens is the one built by extrapolating growth.

Valuation

Start with the size of the demand. At $20.87 the market pays roughly 25.7 dollars for each dollar of annual operating profit, and inverting that gives an assumption of about 34.5% operating-profit growth a year for five years, computed at an 11.6% cost of capital with 4% growth beyond the fifth year. The reference point that matters is how often that has been done. Roughly 23% of comparable fast growers sustained a pace like that across a five-year span. Three in four did not.

Why the requirement is so large becomes clear from the starting margin. Operating profit is 2.7% of revenue, which means the growth being asked for is not incremental. It is a wholesale change in the economics of the business, delivered from a base where a single percentage point of margin is worth more than a year of ordinary sales growth.

The methods split sharply on this one, and the split is informative. Only the forward-growth models reach today's price. Everything else lands beneath it: the price sits about 217% above the asset-value methods, about 137% above the earnings-power methods, and about 33% above the peer-multiple methods. When only the growth lens reaches the price, what is being paid for is durability that static frames cannot express, and the reader should treat it as exactly that. The nearest growth model gets where it gets by assuming the business is valued at the end of its projection on the same EBITDA multiple it carries today, with no compression, which is another way of saying the method presumes the market keeps believing.

Cohort numbers sharpen the picture more than a percentile does. Among online sellers of similar shape, W runs an operating margin near 1.0% on revenue of roughly 12.7 billion dollars, and CPNG near 0.2% on roughly 35.1 billion dollars, so Chewy's 2.7% is genuinely better within e-commerce. Look instead at the pet companies that actually make products and the comparison inverts: FRPT earns an operating margin around 8.1% with a gross margin near 41.1%, and CENT around 8.2%. Chewy sells other people's brands at a discount and keeps a distributor's share. The growth the price requires would move it toward manufacturer economics without it owning much of the manufacturing.

The balance sheet neither supports nor threatens the case, which is itself worth saying. The company funds itself with supplier terms and a "senior secured asset-based credit facility (the \"ABL Credit Facility\") which matures on April 1, 2030", sized at up to 800 million dollars against a borrowing base of inventory and receivables, and it leases its fulfillment centers, offices and clinics rather than owning them, on terms the filing says "generally range from 5 to 15 years". It is not consuming cash. So the downside here is not insolvency; it is derating. Each additional percentage point of cost of capital raises the growth the price requires by about 5.4 percentage points, and at a requirement already near 34.5% a year, there is not much room above it before the assumption stops being a forecast and becomes a hope.

Catalysts

The Q1 2026 report on June 10 was the most recent catalyst and a solid one: net sales up 7.7% to roughly $3.6 billion, a record 7.5% adjusted EBITDA margin, and nearly 200,000 net new active customers reaching 21.5 million. Autoship sales grew over 10% to 84.4% of the mix. The company maintained full-year adjusted EBITDA margin guidance of 6.6% to 6.8% and net sales of about $13.40 to $13.55 billion. The next quarterly print tests whether margin expansion continues against a softer customer-add backdrop.

The forward watch items are specific. First, active customer growth, which management guided toward the low end of its 150,000 to 250,000 per-quarter range citing the current environment; reaccelerating adds would validate the growth premium. Second, the adjusted EBITDA margin trajectory, since the premium multiple needs continued margin expansion and Q1 delivered 130 basis points. Third, Autoship penetration and net sales per active customer, the durability metrics that justify valuing Chewy on forward compounding. Fourth, the competitive response from Amazon, Walmart, and pet pharmacies, the moat-erosion risk that would pressure both growth and margin. Capital allocation is a quieter factor: the company holds net cash and has begun returning capital, so buyback pace against material stock-based compensation is worth tracking.

Peer Cohorts (Per Segment, With Filing Citations)

Core business (reported)

• W (WAYFAIR INC.)
• FY2025 10-K: Part I, Item 1, Business . 22 Table of Contents We expect competition in e-commerce generally to continue to increase. We believe that our ability to compete successfully depends upon many factors both within and beyond our control, including: • the size and composition of our customer base; • the number of suppliers…
• FY2025 10-K: …and trends. We believe these measures are useful indicators of the economic impact of orders fulfilled through our omni-channel platform because they take into account the direct expenses associated with generating and servicing customer demand. These measures provide additional visibility into unit-level performance…
• CPNG (COUPANG, INC.)
• FY2025 10-K: …We operate in a highly competitive industry and we may be unsuccessful in competing against current and future competitors, which could have a negative impact on the success of our business. The industry in which we operate is intensely competitive and we expect that competition will continue to increase. We…
• FY2025 10-K: …of service related to their products and services in a manner that impacts our competitive offerings. If we are unable to use or adapt to operational changes in such services, we may face higher costs for such services, encounter integration or technological barriers, or lose customers, which could cause our…
• CENT (Central Garden & Pet Company)
• FY2025 10-K: …which are more established in their industries and have substantially greater revenue and resources than we do. Our products compete against national and regional products and private label products produced by various suppliers. Our largest competitors in the Pet segment are Spectrum Brands, Mars, Inc. and the J.M…
• FY2025 10-K: …rapidly. To the extent that the key retailers, including retailers in the pet specialty segment, on which we depend lose share to the eCommerce channel, we could lose sales. We continue to make additional investments to access this channel more effectively, but there can be no assurances that any such investments…
• FRPT (FRESHPET, INC.)
• FY2025 10-K: …competition from competitors' products that are sometimes sold at lower prices. Price gaps between our products and our competitors' products may result in market share erosion and harm our business. A number of our competitors have broader product lines, substantially greater financial and other resources and/or…
• FY2025 10-K: …reportable segment: the manufacturing, marketing and distribution of fresh dog food, cat food, and dog treats. 41 Table of Contents ITEM 7a. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS Interest Rate Risk During periods of rising interest rates, our cost of borrowing could increase, the fair value of…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.